Neuroblastoma in a Neonate: A Case Report

Area of Science:

• Pediatric Oncology
• Cancer Genetics

Background:

• Neuroblastoma is a prevalent solid tumor in neonates, accounting for 6-10% of childhood cancers.
• It arises from abnormal neural crest cell proliferation due to oncogene mutations.
• Clinical signs include blueberry rash and subcutaneous nodules; histology shows small, round, blue cell tumors.

Observation:

• Cytogenetic testing is crucial for distinguishing aggressive from non-aggressive neuroblastoma.
• Treatment strategies vary from supportive care to surgery, chemotherapy, and novel targeted therapies.
• Patient outcomes depend significantly on age at diagnosis and specific genetic abnormalities.

Findings:

• This article reviews the current scientific understanding of metastatic familial (congenital) neuroblastoma.
• It includes a case report to illustrate key aspects of the disease.
• Advances in molecular therapies and immunotherapy offer personalized treatment approaches.

Implications:

• Neonatal clinicians require up-to-date knowledge for early detection and management of neuroblastoma.
• Understanding genetic factors is key to predicting neuroblastoma prognosis and treatment response.
• Further research into targeted therapies and immunotherapy is vital for improving survival rates.